TITLE

Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin

AUTHOR(S)
Brixner, Diana I.; Xin Ye; Teng-Chiao Chu; Blumentals, William A.; Hassanein, Tarek I.
PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/15/2009, Vol. 66 Issue 24, p2171
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study that compares peginterferon of alfa-2a plus ribavirin with peginterferon alfa-2b plus ribavirin administered to patients with hepatitis C. It notes that the study aims to determine which treatment method gives the higher percentage of treatment effectiveness and lesser medical cost. It states that hepatitis C treatment that uses peginterferon alfa-2a plus ribavirin reduces health care cost and at the same time increases treatment persistence.
ACCESSION #
46823213

 

Related Articles

  • Update on the Treatment of Patients With Non–Genotype 1 Hepatitis C Virus Infection. Mangia, Alessandra; Mottola, Leonardo; Piazzolla, Valeria // Clinical Infectious Diseases;May2013, Vol. 56 Issue 9, p1294 

    We focus on the treatment of hepatitis C virus genotypes 2 and 3 with coverage of clinical trials on short-duration treatment course, use of weight-based ribavirin, impact of cirrhosis on treatment decisions, and retreatment of patients with previous treatment failure.Current treatment for...

  • Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Neukam, K.; Mira, J.; Gilabert, I.; Claro, E.; Vázquez, M.; Cifuentes, C.; García-Rey, S.; Merchante, N.; Almeida, C.; Macías, J.; Pineda, J. // European Journal of Clinical Microbiology & Infectious Diseases;Jun2012, Vol. 31 Issue 6, p1225 

    A considerable number of patients undergoing methadone maintenance treatment (MMT) are not considered for treatment against hepatitis C virus (HCV) infection due to a possible lower adherence and efficacy in this population. We aimed to compare the response rates to HCV treatment in patients...

  • Peginterferon-α-2a/ribavirin.  // Reactions Weekly;10/1/2011, Issue 1371, p30 

    The article describes the case of a 53-year-old man who developed bronchial cast expectoration while being treated with peginterferon-&alpha-2a and ribavirin for chronic hepatitis C.

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;10/20/2012, Issue 1424, p40 

    The article describes the case of a 62-year-old man who developed branch retinal artery occlusion (BRAO) and central retinal vein occlusion (CRVO) during treatment with peginterferon-α-2b and ribavirin for chronic hepatitis C infection.

  • Filgrastim/peginterferon-α-2a/ribavirin.  // Reactions Weekly;1/29/2011, Issue 1336, p22 

    The article describes the case report of a 54-year-old female patient with chronic hepatitis C, and who developed severe recurrent neutropenia, thrombocytopenia and agranulocytosis during long-term therapy with SC peginterferon-α-2a combined with ribavirin.

  • Peginterferon/ribavirin.  // Reactions Weekly;11/13/2010, Issue 1327, p30 

    The article describes the case of depression and fatigue in two men while receiving treatment with peginterferon and ribavirin for chronic hepatitis C.

  • CORRECTIONS.  // JAMA: Journal of the American Medical Association;11/13/2013, Vol. 310 Issue 18, p1987 

    A correction to the article "Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics: A Randomized Clinical Trial" in the Augst 28, 2013 issue is presented.

  • Interferon-α-2b/ribavirin.  // Reactions Weekly;1/8/2011, Issue 1333, p25 

    The article describes the case of a 30-year-old man who developed Vogt-Koyanagi-Harada (VKH) diseases during treatment with interferon-α-2b and ribavirin for a chronic hepatitis C virus infection.

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;6/23/2012, Issue 1407, p34 

    The article describes the case of a 44-year-old woman who developed hyperpigmentation of the tongue while receiving treatment with peginterferon-α-2b and ribavirin for hepatitis C virus (HCV) infection.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics